Education
About Us
Working with TipRanks
Follow Us
Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
KLRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.96 - $24.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)15.29K
Market Cap
$147.63M
Enterprise Value-$28.55M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.75
Shares Outstanding18,702,414
10 Day Avg. Volume30,331
30 Day Avg. Volume15,291
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $7.96 and its highest was $24.15 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $147.63M.
When is Kalaris Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on Aug 01, 2024. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Overvalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 18,702,414 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 4.956%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
---
Kalaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 19.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.56%
12-Months-Change
Fundamentals
Return on Equity
-45.37%
Trailing 12-Months
Asset Growth
-37.87%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
---
KLRS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering KLRS
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-37.58%
reiterated a sell rating 8 months ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -37.58% per trade.
---